All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Join our

Treatment sequencing for anemic myelofibrosis

with Jean-Jacques Kiladjian & Angela Fleischman

Monday, February 26, 2024 | 16:30 CET

This independent educational activity is supported by Bristol Myers Squibb. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.


The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

How should we define disease modification in MF?

Jun 27, 2022
Learning objective: After reading this article, learners will be able to cite a new clinical development in myelofibrosis.

Bookmark this article

During the ESH 9th Translational Research Conference: Myeloproliferative Neoplasms, the MPN Hub was pleased to speak to Naveen Pemmaraju, MD Anderson Cancer Center, Houston, US. We asked, How should we define disease modification in myelofibrosis (MF)?

How should we define disease modification in MF?

Pemmaraju begins by explaining that since there is currently only one approved drug class for MF treatment (JAK inhibitors), the outcomes for patients can be variable. Pemmaraju goes on to discuss the importance of measuring disease, and how the introduction of new combination therapies could lead to new response criteria. Finally, Pemmaraju talks about a review article published in 'Cancer' earlier this year (2022), led by himself and Professor Adam J. Mead, University of Oxford, Oxford, UK.



Subscribe to get the best content related to MPN delivered to your inbox